2023 annual financial data
BioCryst Pharmaceuticals 2023 Operating margin
BioCryst Pharmaceuticals 2023 operating margin with verified reported values.
Direct answer
Operating margin was -31.29%.
Operating income was -103,709,000 USD and net income was -226,539,000 USD.
Operating cash flow was -95,141,000 USD.
Get free BioCryst Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 331,412,000 USD
- Operating income
- -103,709,000 USD
- Net income
- -226,539,000 USD
- Operating cash flow
- -95,141,000 USD